Can it be hope for Merck? The selling point is no weight gain. Trials show a decrease of 0.77 in A1c over 12 weeks.
A new class of diabetes medication
More in Uncategorized
Past Week
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
Elite access vs. public scrutiny: Medication disparities exposed
-
The Supreme Court must consider science, not pseudo-science, in public health rulings
-
Medicine’s struggle for inclusivity
-
Non-opioid post-op pain relief [PODCAST]
-
GLP-1 medications like Wegovy are effective metabolic health tools for teens with insulin resistance
-
Past 6 Months
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Elite access vs. public scrutiny: Medication disparities exposed
-
When the doctor’s office becomes a confession booth
-
The abuser’s playbook: the weaponization of mental health
-
How Enhanced Recovery After Surgery solves our opioid problems
-
Real pain deserves real treatment
-
Recent Posts
-
Non-opioid post-op pain relief [PODCAST]
-
I had a (incorrect) memory screening. Have you even had one?
-
Why doctors should embrace uncertainty for better patient outcomes
-
Medicine’s struggle for inclusivity
-
Addiction treatment, legal troubles, and the role of the DEA [PODCAST]
-
Embracing vulnerability: a doctor’s journey of healing and connection
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
